Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

NCT01259323 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis

Interventions

BIOLOGICAL: REGN668
BIOLOGICAL: REGN668
BIOLOGICAL: REGN668

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]